tradingkey.logo

Twist Bioscience Corp

TWST
31.320USD
+0.360+1.16%
終値 11/11, 16:00ET15分遅れの株価
1.88B時価総額
損失額直近12ヶ月PER

Twist Bioscience Corp

31.320
+0.360+1.16%

詳細情報 Twist Bioscience Corp 企業名

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. It is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. It makes products for use across many industries, including healthcare, industrial chemicals, agriculture and academic research.

Twist Bioscience Corpの企業情報

企業コードTWST
会社名Twist Bioscience Corp
上場日Oct 31, 2018
最高経営責任者「CEO」Dr. Emily M. Leproust, Ph.D.
従業員数923
証券種類Ordinary Share
決算期末Oct 31
本社所在地681 Gateway Blvd.
都市SOUTH SAN FRANCISCO
証券取引所NASDAQ Global Select Consolidated
United States of America
郵便番号94080
電話番号18007190671
ウェブサイトhttps://www.twistbioscience.com/
企業コードTWST
上場日Oct 31, 2018
最高経営責任者「CEO」Dr. Emily M. Leproust, Ph.D.

Twist Bioscience Corpの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
429.81K
-1.12%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
141.81K
-1.91%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
66.11K
-1.52%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
61.66K
-1.73%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
22.25K
+25.16%
Dr. Melissa A. Starovasnik, Ph.D.
Dr. Melissa A. Starovasnik, Ph.D.
Independent Director
Independent Director
15.81K
+39.44%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
15.43K
+110.29%
Mr. Jan Johannessen
Mr. Jan Johannessen
Independent Director
Independent Director
12.60K
+55.04%
Mr. Robert Werner
Mr. Robert Werner
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
429.81K
-1.12%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
141.81K
-1.91%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
66.11K
-1.52%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
61.66K
-1.73%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
22.25K
+25.16%

収益内訳

通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
NGS tools
55.28M
57.55%
Synthetic genes
27.68M
28.82%
Antibody discovery
5.61M
5.84%
Oligo pools
5.42M
5.65%
DNA libraries
2.06M
2.14%
地域別USD
会社名
収益
比率
Americas
59.39M
61.82%
EMEA
30.74M
32.00%
APAC
5.93M
6.17%
事業別
地域別
事業別USD
会社名
収益
比率
NGS tools
55.28M
57.55%
Synthetic genes
27.68M
28.82%
Antibody discovery
5.61M
5.84%
Oligo pools
5.42M
5.65%
DNA libraries
2.06M
2.14%

株主

更新時刻: Sat, Nov 8
更新時刻: Sat, Nov 8
株主統計
種類
株主統計
株主統計
比率
Artisan Partners Limited Partnership
10.62%
ARK Investment Management LLC
10.60%
The Vanguard Group, Inc.
9.53%
BlackRock Institutional Trust Company, N.A.
8.05%
William Blair Investment Management, LLC
6.47%
他の
54.72%
株主統計
株主統計
比率
Artisan Partners Limited Partnership
10.62%
ARK Investment Management LLC
10.60%
The Vanguard Group, Inc.
9.53%
BlackRock Institutional Trust Company, N.A.
8.05%
William Blair Investment Management, LLC
6.47%
他の
54.72%
種類
株主統計
比率
Investment Advisor
63.08%
Investment Advisor/Hedge Fund
37.18%
Hedge Fund
12.55%
Research Firm
5.03%
Individual Investor
2.24%
Pension Fund
1.60%
Bank and Trust
0.40%
Family Office
0.17%
Insurance Company
0.07%

機関投資家保有株

更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
566
71.88M
119.09%
+752.75K
2025Q2
575
70.44M
116.72%
-302.44K
2025Q1
585
70.23M
117.22%
-1.63M
2024Q4
578
67.47M
113.11%
-8.03M
2024Q3
588
67.80M
115.74%
-8.48M
2024Q2
579
66.59M
114.39%
-10.53M
2024Q1
565
68.18M
117.94%
-8.61M
2023Q4
559
67.81M
117.39%
-11.70M
2023Q3
560
68.09M
118.66%
-11.36M
2023Q2
577
69.42M
121.49%
-5.07M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
Artisan Partners Limited Partnership
6.41M
10.62%
+1.35M
+26.67%
Sep 30, 2025
ARK Investment Management LLC
6.40M
10.6%
+158.85K
+2.54%
Jun 30, 2025
The Vanguard Group, Inc.
5.82M
9.64%
-36.15K
-0.62%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.86M
8.05%
+226.25K
+4.89%
Jun 30, 2025
William Blair Investment Management, LLC
3.91M
6.47%
+99.74K
+2.62%
Jun 30, 2025
State Street Investment Management (US)
2.50M
4.14%
-192.68K
-7.15%
Jun 30, 2025
EdgePoint Investment Group Inc.
2.39M
3.95%
+1.27M
+114.33%
Jun 30, 2025
Invesco Advisers, Inc.
2.29M
3.8%
-1.04M
-31.23%
Jun 30, 2025
Point72 Asset Management, L.P.
2.16M
3.58%
+725.54K
+50.64%
Jun 30, 2025
Amova Asset Management Co., Ltd.
2.30M
3.81%
-116.36K
-4.82%
Jun 30, 2025
詳細を見る

関連ETF

更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
銘柄名
比率
ARK Genomic Revolution ETF
5.08%
iShares Genomics Immunology and Healthcare ETF
3.56%
Global X Genomics & Biotechnology ETF
1.85%
ROBO Global Healthcare Technology & Innovation ETF
1.74%
ARK Innovation ETF
1.55%
WisdomTree BioRevolution Fund
1.53%
Franklin Genomic Advancements ETF
0.98%
SPDR S&P Biotech ETF
0.83%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.57%
Direxion Daily S&P Biotech Bull 3X Shares
0.43%
詳細を見る
ARK Genomic Revolution ETF
比率5.08%
iShares Genomics Immunology and Healthcare ETF
比率3.56%
Global X Genomics & Biotechnology ETF
比率1.85%
ROBO Global Healthcare Technology & Innovation ETF
比率1.74%
ARK Innovation ETF
比率1.55%
WisdomTree BioRevolution Fund
比率1.53%
Franklin Genomic Advancements ETF
比率0.98%
SPDR S&P Biotech ETF
比率0.83%
First Trust Nasdaq Lux Digi Health Solutions ETF
比率0.57%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.43%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
データなし
日付
種類
比率
データなし
KeyAI